Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Tizos powder for injection

Dexa Medica

Ingredients in every vial

Ceftizoxime 1000 mg

Each package contains

1 vial of 1 g

Dosage form

Powder for injection

Dosage formPowder for Injection

Flavour

None

W.H.O. classification

J01D
J01D

A.T.C. Level 1

Anatomical Main group

J - Antiinfectives for systemic use
J01D

A.T.C. Level 2

Therapeutic subgroup

J01 - Antibacterials for Systemic Use
J01D

A.T.C. Level 3

Pharmacological subgroup

J01D - Other Beta-Lactam Antibacterials in ATC

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Indication

The following infections caused by ceftizoxime susceptible Streptococcus sp. (excluding Enterococci), Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella sp., Proteus sp., Serratia sp., Enterobacter sp., Citrobacter sp., Peptococcus sp., Peptostreptococcus sp., and Bacteroides sp.
Septicemia, bacterial endocarditis
Secondary infections of wounds or burns
Bronchitis, infected bronchiectasis, secondary infections of chronic respiratory tract diseases, pneumonia, pulmonary suppuration, pyothorax
Cholangitis, cholecystitis
Peritonitis
Pyelonephritis, cystitis, prostatitis
Meningitis caused by H. influenzae

Dosage

18 YEARS OLD AND ABOVE
• Intravenous injection
Usually 0.5-2 g/day of ceftizoxime is administered intravenously in 2-4 equally divided doses, increased to 4 g/day for severe or intractable infections, according to the age and condition of the patient.
• Intramuscular injection
Usually 0.5-2 g/day of ceftizoxime is administered intramuscularly in 2-4 equally divided doses, according to the age and condition of the patient

6 MONTHS TO 18 YEARS OLD
• Intravenous injection
For children 6 months or older usually 40-80 mg/kg/day of ceftizoxime in 2-4 equally divided doses, increased to 120 mg/kg/day for severe or intractable infections, according to the age and condition of the patient.